DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cytarabine (Cytarabine) - Nausea - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Nausea (82)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include nausea. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 82   Next >>

Possible Cytarabine side effects in male

Reported by a health professional (non-physician/pharmacist) from Netherlands on 2012-08-17

Patient: male, weighing 68.0 kg (149.6 pounds)

Reactions: Dyspnoea, Vomiting, Nausea, Hyperreflexia, Encephalopathy, Extensor Plantar Response, Endophthalmitis, Lung Consolidation, Respiratory Failure, Emotional Disorder, CSF Pressure Increased, Reflexes Abnormal, Lethargy

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cytarabine
    Dosage: 3600 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-25

Clofarabine
    Dosage: 18 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-25

Amsacrine
    Dosage: 220 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-28

Other drugs received by patient: Valaciclovir



Possible Cytarabine side effects in male

Reported by a health professional (non-physician/pharmacist) from Netherlands on 2012-08-02

Patient: male, weighing 68.0 kg (149.6 pounds)

Reactions: Dyspnoea, Vomiting, Nausea, Encephalopathy, Hyperreflexia, Extensor Plantar Response, Lung Consolidation, Respiratory Failure, CSF Pressure Increased, Emotional Disorder, Reflexes Abnormal, Lethargy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 18 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-25

Cytarabine
    Dosage: 3600 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-25

Amsacrine
    Dosage: 220 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-28

Other drugs received by patient: Valaciclovir



Possible Cytarabine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-25

Patient: female, weighing 88.0 kg (193.6 pounds)

Reactions: Enterobacter Infection, Gamma-Glutamyltransferase Increased, Diarrhoea, Nausea, Sepsis, Oxygen Supplementation, Epilepsy, Renal Failure Acute

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: unk
    Indication: Acute Leukaemia

Filgrastim
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cytarabine
    Dosage: unk
    Indication: Acute Leukaemia



Possible Cytarabine side effects in 59 year old male

Reported by a physician from United States on 2012-07-19

Patient: 59 year old male, weighing 83.6 kg (183.9 pounds)

Reactions: Vomiting, Nausea

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ofatumumab
    Dosage: 1000mg cyclic
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-04-30

Dexamethasone
    Dosage: 40mg every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-04-30

Cisplatin
    Dosage: 100mgm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-04-30

Cytarabine
    Dosage: 4gm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-05-01



Possible Cytarabine side effects in

Reported by a physician from United Kingdom on 2012-07-17

Patient:

Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole



Possible Cytarabine side effects in 61 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-11

Patient: 61 year old female

Reactions: Rash Pustular, Nausea, Pyrexia, Oral Herpes, Erythema, Sensorimotor Disorder, Haemodialysis, Stem Cell Transplant, Mucosal Inflammation, Epidermal Necrosis, Mental Disorder, Nervous System Disorder, Renal Tubular Necrosis, Blister, Renal Failure Acute

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine

Other drugs received by patient: Vancomycin Hydrochloride; Melphalan Hydrochloride; Carmustine; Etoposide; Cefepime Hydrochloride



Possible Cytarabine side effects in

Reported by a physician from United Kingdom on 2012-07-10

Patient:

Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



Possible Cytarabine side effects in 59 year old male

Reported by a physician from United States on 2012-06-28

Patient: 59 year old male, weighing 83.6 kg (183.9 pounds)

Reactions: Vomiting, Nausea

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 4gm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-05-01

Dexamethasone
    Dosage: 40mg every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-04-30

Ofatumumab
    Dosage: 1000mg cyclic
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-04-30

Cisplatin
    Dosage: 100mgm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-04-30



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-06-28

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



Possible Cytarabine side effects in

Reported by a individual with unspecified qualification from United States on 2012-06-27

Patient:

Reactions: Blood Bilirubin Increased, Vomiting, Nausea, Anaemia, Rash, Fatigue, Aspartate Aminotransferase Increased, Adverse Event, Neutropenia, Rash Maculo-Papular, Thrombocytopenia, Decreased Appetite

Adverse event resulted in: death

Drug(s) suspected as cause:
Revlimid
    Administration route: Oral

Revlimid
    Dosage: 10mg-25mg
    Administration route: Oral

Revlimid
    Dosage: 50 milligram
    Administration route: Oral

Revlimid
    Dosage: 10mg-25mg
    Administration route: Oral

Cytarabine
    Dosage: 1.5 milligram/sq. meter

Cytarabine
    Dosage: 10 milligram



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-25

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Stomatitis, Vomiting, Dyspnoea, Nausea, Gastrointestinal Toxicity, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



Possible Cytarabine side effects in 70 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-14

Patient: 70 year old female, weighing 57.0 kg (125.4 pounds)

Reactions: White Blood Cell Count Decreased, Nausea, Muscular Weakness, Failure To Thrive, Fatigue, Dehydration, Neutrophil Count Decreased, Decreased Appetite, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: last dose on 03mar12,17apr12;9540mg,no of courses: 2
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-02-27

Sprycel
    Dosage: d6-26,last dose on 23mar12,06may12;1100mg,no of courses: 2
    Administration route: Oral
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-02-27



Possible Cytarabine side effects in 60 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04

Patient: 60 year old male

Reactions: Nausea, Pancytopenia, Toxicity To Various Agents

Drug(s) suspected as cause:
Pegfilgrastim
    Dosage: 6 mg, unk on day 6
    Indication: Acute Myeloid Leukaemia

Gemtuzumab Ozogamicin
    Dosage: 3 mg/m2 on day 1
    Indication: Acute Myeloid Leukaemia

Filgrastim
    Dosage: 5 a?g/kg/day on day 1-5
    Indication: Acute Myeloid Leukaemia

Fludarabine Phosphate
    Dosage: 30 mg/m2/day over 30 minutes on days 1-5
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: 2g/m2/day over 4 hours on days 1-5
    Indication: Acute Myeloid Leukaemia



Possible Cytarabine side effects in 7 year old female

Reported by a individual with unspecified qualification from United States on 2012-05-17

Patient: 7 year old female, weighing 39.0 kg (85.8 pounds)

Reactions: Retching, Nausea, Hypophagia, Hypertriglyceridaemia, Decreased Appetite

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade
    Dosage: 1.3 mg/m**2; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28
    End date: 2012-04-17

Doxorubicin HCL
    Dosage: 60 mg/m**2;qd;iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28
    End date: 2012-03-01

Oncaspar
    Dosage: 2500 iu/m**2; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28
    End date: 2012-03-22

Cytarabine
    Dosage: 70 mg;x1;inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28
    End date: 2012-02-28

Vincristine
    Dosage: 1.5 mg/m**2; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28
    End date: 2012-03-22

Prednisone TAB
    Dosage: 20 mg/m**2;qd;po
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28
    End date: 2012-03-01

Methotrexate
    Dosage: 500 mg/m**2; inth; 4500 mg/m**2; iv
    Indication: Acute Lymphocytic Leukaemia
    End date: 2012-04-10

Methotrexate
    Dosage: 500 mg/m**2; inth; 4500 mg/m**2; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-28

Methotrexate
    Dosage: 500 mg/m**2; inth; 4500 mg/m**2; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-10
    End date: 2012-04-14



Possible Cytarabine side effects in 31 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-15

Patient: 31 year old male

Reactions: Vomiting, Nausea, Leukaemic Infiltration, Pyrexia, Appendicitis, Abdominal Pain Upper

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 200 mg/m2
    Indication: Acute Promyelocytic Leukaemia

Idarubicin Hydrochloride
    Dosage: 12 mg/m2
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Tretinoin



Possible Cytarabine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-05-14

Patient: female, weighing 43.8 kg (96.4 pounds)

Reactions: Disinhibition, Hypoaesthesia Oral, Protrusion Tongue, Balance Disorder, Oxygen Saturation Decreased, Grimacing, Nausea, Blepharospasm, Abnormal Behaviour, Body Temperature Decreased, Haemoglobin Decreased, Affect Lability, Heart Rate Increased, Platelet Count Decreased, Memory Impairment, Inappropriate Affect, Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Hydrocortisone
    Dosage: 45 mg
    End date: 2012-04-25

Daunorubicin Hydrochloride
    Dosage: 140 mg
    End date: 2012-03-28

Mercaptopurine
    Dosage: 1150 mg
    End date: 2012-04-24

Vincristine Sulfate
    Dosage: 4 mg
    End date: 2012-05-03

Cytarabine
    Dosage: 1090 mg
    End date: 2012-04-25

PEG-L-Aspraginase (Pegasparagase, Oncospar)
    Dosage: 3375 iu
    End date: 2012-04-25

Methotrexate
    Dosage: 45 mg
    End date: 2012-04-25

Cyclophosphamide
    Dosage: 2800 mg
    End date: 2012-05-09



Possible Cytarabine side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-14

Patient: female, weighing 92.8 kg (204.2 pounds)

Reactions: Vomiting, Nausea, Gastroenteritis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Bortezomib
    Dosage: 0.7mg/m2 d1, d4, d8, d11 iv 12/31, 1/3, 1/7, 1/10
    Indication: Acute Myeloid Leukaemia

Mitoxantrone
    Dosage: 6mg/m2 (mito) qdx6 iv 12/31, 1/1-5
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 80mg/m2 (vp-16) qdx6 iv 12/31, 1/1-5
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: 1000mg/m2 ara-c qdx6 iv 12/31, 1/1-5
    Indication: Acute Myeloid Leukaemia

Other drugs received by patient: Lorazepam; Prochlorperazine; Acyclovir; Voriconazole; Omeprazole; Duloxetime Hydrochloride; Olanzapine; Amlodipine Besylate and Benazepril HCL



Possible Cytarabine side effects in 1 year old female

Reported by a physician from United States on 2012-05-10

Patient: 1 year old female, weighing 7.6 kg (16.8 pounds)

Reactions: Dyspnoea, Vomiting, Hypothermia, Nausea, Chills, Pyrexia, Peripheral Sensory Neuropathy, Sinus Bradycardia, Hypokalaemia, Diarrhoea, Ileus, Hypoalbuminaemia, Lung Infiltration, Candidiasis, Influenza Like Illness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Prednisone TAB
    Dosage: 20 mg/m2, unk
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-24

Cytarabine
    Dosage: unk mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    End date: 2012-03-22

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23



Possible Cytarabine side effects in male

Reported by a individual with unspecified qualification from United States on 2012-05-07

Patient: male, weighing 98.6 kg (216.9 pounds)

Reactions: Nausea, Blood Cholesterol Increased, Thrombophlebitis, Blood Triglycerides Increased, Failure To Thrive

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 1360 mg

Methotrexate
    Dosage: 60 mg

Vincristine Sulfate
    Dosage: 4 mg

Cyclophosphamide
    Dosage: 2300 mg

Mercaptopurine
    Dosage: 2000 mg

PEG-L-Asparaginase (K-H)
    Dosage: 5700 unt



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-25

Patient:

Reactions: Vomiting, Pneumonia, Nausea, Febrile Neutropenia, Rash, Hypokalaemia, Diarrhoea, Sepsis, Oedema, Decreased Appetite

Drug(s) suspected as cause:
Cladribine
    Indication: Acute Myeloid Leukaemia Recurrent

Cytarabine
    Indication: Acute Myeloid Leukaemia Recurrent

Neupogen
    Indication: Acute Myeloid Leukaemia Recurrent

Imatinib Mesylate
    Administration route: Oral
    Indication: Acute Myeloid Leukaemia Recurrent



Possible Cytarabine side effects in male

Reported by a individual with unspecified qualification from United States on 2012-04-16

Patient: male, weighing 108.3 kg (238.3 pounds)

Reactions: Vomiting, Nausea, Orthostatic Hypotension, Muscular Weakness, Blood Lactic Acid Increased, Malaise, Sepsis, Tachypnoea, Sinus Tachycardia, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 1638 mg
    End date: 2011-10-31

Daunorubicin HCL
    Dosage: 420 mg
    End date: 2011-10-27



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-04-12

Patient:

Reactions: Nausea, Haemorrhage, Pain, Rash, Pyrexia, Fatigue, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Revlimid
    Dosage: 5mg escalated in 5mg increments to 25mg/day max
    Administration route: Oral

Cytarabine
    Dosage: 100 milligram/sq. meter

Idarubicin HCL
    Dosage: 12 milligram/sq. meter



Possible Cytarabine side effects in female

Reported by a physician from United States on 2012-04-12

Patient: female, weighing 110.0 kg (242.0 pounds)

Reactions: Nausea, Hyperglycaemia, Headache, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: 30 mg 15 mg intrathecal

Cytarabine
    Dosage: 70 mg

Daunorubicin HCL
    Dosage: 232 mg days 1,8,15,22

Vincristine Sulfate
    Dosage: 8 mg 2mg on days 1,8,15,22

Methylprednisolone
    Dosage: 3920 mg, 60 mg/m2 daily

PEG-L Asparaginase (K-H)
    Dosage: 5750 unit



Possible Cytarabine side effects in 10 year old female

Reported by a physician from United States on 2012-04-05

Patient: 10 year old female, weighing 20.8 kg (45.8 pounds)

Reactions: Abdominal Pain, Headache, Caecitis, Hypokalaemia, Fungaemia, Hypoxia, Rash Pustular, Back Pain, Nausea, Pain in Extremity, Hypotension, Hyponatraemia, Febrile Neutropenia, Hypophosphataemia, Respiratory Tract Infection, Neuralgia, Enterocolitis Infectious

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Prednisone
    Dosage: 20 mg/m2, cyclic
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-12-14
    End date: 2011-12-27

Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-12-14
    End date: 2011-12-14

Cytarabine
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia
    End date: 2011-12-29

Pegaspargase
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-12-15
    End date: 2011-12-29

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-12-14
    End date: 2011-12-29

Methotrexate
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia
    End date: 2011-12-29

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-12-14
    End date: 2011-12-17

Hydrocortisone
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia
    End date: 2011-12-29



Possible Cytarabine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-04-05

Patient: female, weighing 53.6 kg (117.9 pounds)

Reactions: Abdominal Pain, Tachycardia, Faeces Discoloured, Haematemesis, Posterior Reversible Encephalopathy Syndrome, Enterocolitis, Nausea, Hepatic Steatosis, Convulsion, Cholelithiasis, Mallory-Weiss Syndrome, Bacteraemia, Platelet Count Decreased, Ammonia Increased, Neutropenia, Hypertension, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mercaptopurine
    Dosage: 2500 mg

Cyclophosphamide
    Dosage: 2900 mg

Cytarabine
    Dosage: 216 mg



Possible Cytarabine side effects in 67 year old male

Reported by a individual with unspecified qualification from Germany on 2012-04-05

Patient: 67 year old male

Reactions: Disorientation, Injection Site Erythema, Thrombocytopenia, Melaena, Epistaxis, Vomiting, Dyspnoea, Nausea, Neutropenic Sepsis, Febrile Neutropenia, Skin Disorder, Hepatic Enzyme Increased, Syncope, Bacteraemia, Diarrhoea, Neutropenia, Hypertension, Leukopenia

Drug(s) suspected as cause:
Cytarabine

Vidaza

Daunorubicin HCL



Possible Cytarabine side effects in 1 year old female

Reported by a consumer/non-health professional from United States on 2012-04-05

Patient: 1 year old female, weighing 7.6 kg (16.8 pounds)

Reactions: Vomiting, Dyspnoea, Hypothermia, Nausea, Chills, Pyrexia, Peripheral Sensory Neuropathy, Sinus Bradycardia, Diarrhoea, Lung Infiltration, Influenza Like Illness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk mg, cyclic
    Indication: B Precursor Type Acute Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Prednisone
    Dosage: 20 mg/m2, unk
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-24



Possible Cytarabine side effects in female

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-04-04

Patient: female

Reactions: Pyrexia, Headache, Oedema Peripheral, Thrombocytopenia, Epistaxis, Cough, Back Pain, Vomiting, Nausea, Rash, Tongue Coated, Mucosal Inflammation, Soft Tissue Infection, Bacteraemia, Diarrhoea, Venous Thrombosis, Neutropenia, Hypertension, Leukopenia

Drug(s) suspected as cause:
Vidaza

Vidaza

Cytarabine

Cytarabine
    Dosage: 1g/sqm

Daunorubicin HCL



Possible Cytarabine side effects in 67 year old male

Reported by a individual with unspecified qualification from Germany on 2012-04-03

Patient: 67 year old male

Reactions: Disorientation, Injection Site Erythema, Thrombocytopenia, Melaena, Epistaxis, Dyspnoea, Vomiting, Nausea, Neutropenic Sepsis, Febrile Neutropenia, Skin Disorder, Hepatic Enzyme Increased, Syncope, Bacteraemia, Diarrhoea, Neutropenia, Hypertension, Leukopenia

Drug(s) suspected as cause:
Vidaza

Cytarabine

Daunorubicin HCL



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017